Regeneron

News

Truveta's co-founder and chief executive, Terry Myerson

Regeneron, Illumina join $320m Truveta investment

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

News

Regeneron builds in eye disease tech with Oxular takeover

Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.

News

ASH: Regeneron plays its PNH hand

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

Closeup of vials on a conveyor at Amgen facility

Legal win leads Amgen to at-risk launch of Eylea biosimilar

Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal

News

Sanofi's Dupixent scores double COPD win in US, China

Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.

Oncology

Israel Lowy from Regeneron interview with Nicole Raleigh

ESMO 2024 - Israel (Izzy) Lowy

ESMO 2024, which followed hot on the heels of this year’s World Conference on Lung Cancer, was abuzz with data around PD-1 inhibitors, LAG-3 inhibitors, and the possibilities for using exis

Regeneron, Illumina join $320m Truveta investment

Regeneron builds in eye disease tech with Oxular takeover

ASH: Regeneron plays its PNH hand

Legal win leads Amgen to at-risk launch of Eylea biosimilar

Sanofi's Dupixent scores double COPD win in US, China

ESMO 2024 - Israel (Izzy) Lowy

EMA seeks input on virtual alternative to animal test

Using AI-driven synthetic personas to take your insights fur...

Regeneron

Editor's Picks